We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Probes Detect Enteropathogens in Stool

By LabMedica International staff writers
Posted on 19 Oct 2011
A multiplex polymerase chain reaction (PCR) assay has been developed to identify four eukaryotic enteropathogens in stool samples.

Cyclospora, Cystoisospora, and Microsporidia are eukaryotic enteropathogens that are difficult to detect in stool samples because they require special stains and microscopy.

Scientists collaborating with the University of Virginia (Charlottesville, VA, USA) developed a multiplex PCR with four primer sets to amplify two protozoan parasites Cyclospora cayetanensis and Cystoisospora belli, and two microsporidian parasites, Enterocytozoon bieneusi, and Encephalitozoon intestinalis. The amplicons were detected through specific probes coupled to Luminex beads. More...
Sensitivity of the assay was evaluated using E. intestinalis spores and revealed detection of 101 spores spiked into stool. No cross-reactivity was observed with samples containing a variety of other pathogenic protozoa, helminths, bacteria or viruses.

The assay was evaluated on 236 diarrheal fecal specimens from Thailand, Tanzania, Indonesia, and The Netherlands that had been previously tested by microscopy. Detection of the amplicons was performed by the BioPlex 200 (Bio-Rad; Hercules, CA, USA) or the Luminex 100 (Luminex Corporation; Austin, TX, USA). The multiplex assay yielded a sensitivity of 87% to 100% and a specificity of 88% to 100%. Microscopy-negative/PCR-positive samples had lower Luminex values, suggesting they were true positives, but with a lower burden of infections. The limit of detection was 102 plasmid copies for Cystoisospora and Enterocytozoon bieneusi and 103 plasmid copies for Cyclospora.

The authors concluded that the assay is robust, with field-testing for this work having been successfully performed on-site in diverse locations including Thailand, Tanzania, Virginia, and The Netherlands. The molecular assay was validated on a large number of specimens for important eukaryotic enteropathogens that can be used in isolation or in the context of additional enteropathogen screening algorithms. The study was published on October 6, 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

University of Virginia
Bio-Rad
Luminex Corporation




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.